



September 4, 2014

BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies

RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2014 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq:BCRX) today announced its participation in a consultation on potential Ebola therapies and vaccines hosted by the [World Health Organization](#) (WHO). The meeting is scheduled to take place September 4-5 in Geneva, Switzerland. According to the WHO, "The consultation has been convened to gather expertise about the most promising experimental therapies and vaccines and their role in containing the Ebola outbreak in west Africa." The meeting agenda and other information are available at:

<http://www.who.int/mediacentre/events/meetings/2014/ebola-interventions/en/>

At the request of the WHO, BioCryst has furnished a one-page executive summary and a slide summary regarding BioCryst's broad spectrum antiviral [BCX4430](#) as a drug candidate for the treatment of Ebola Virus Disease and other hemorrhagic fever virus diseases. These documents summarize: nonclinical disease model and safety research results; anticipated timelines for filing an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration to commence human safety studies of BCX4430; and projections for BCX4430 drug supply.

Electronic versions of the executive summary and presentation provided to the WHO by BioCryst are available on the corporate website at www.biocryst.com.

About the BSAV Program & BCX4430

The objective of BioCryst's BSAV research program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to health and national security. The lead BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S. Government Agencies following the Animal Rule regulatory pathway.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including [BCX4161](#) and several second generation compounds; [peramivir](#), a viral neuraminidase inhibitor for the treatment of influenza, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that BioCryst or its licensees may not be able to enroll the required number of subjects in planned clinical trials of its product candidates and that such clinical trials, may not be successfully completed; that the Company or its licensees may not commence as expected additional pre-clinical studies or human clinical trials may not be commenced as expected or such studies may not be successfully completed; that the FDA may require additional studies beyond those planned for BCX4430, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold BCX4430, or withhold market approval for product candidates; that the Company may not be able to obtain additional funding for BCX4430; that government funding or other contracts for BCX4430 may have certain terms and conditions, including termination provisions, that subject the Company to additional risks; that the Company may lose current funding for the program; that the Company may never file an IND for BCX4430; that its actual financial results may not be consistent with its expectations, including that 2014 operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form

8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.

BCRXW

CONTACT: Robert Bennett

BioCryst Pharmaceuticals

+1-919-859-7910



Source: BioCryst Pharmaceuticals

News Provided by Acquire Media